Pfizer Inc. Chief Executive Officer Ian Read said he is reviewing the possible sale or spinoff of four divisions with $18.3 billion in annual revenue, led by the company’s third-biggest unit, established products.
Pfizer Inc. investors are pushing for a spinoff of the drugmaker’s nutrition business that would command a price tag of $6.8 billion and deliver more than twice the gains of the U.S. stock market.
Investors should buy Bristol-Myers Squibb Co. calls as approval for a melanoma treatment may boost the drugmaker’s stock price, Goldman Sachs Group Inc. said.
Bristol-Myers Squibb Co. partner Otsuka Pharmaceutical Co. won a court ruling that will prevent generic versions of the schizophrenia treatment Abilify from entering the U.S. market until April 2015.
Two cancer drugs from Bristol-Myers Squibb Co. could change the standard of care for patients with deadly skin and blood malignancies, according to new studies.
"We believe shares are trading lower following management's disclosure on the conference call of a higher-than- expected tax rate for AbbVie."
- Linda Bannister on Oct 17, 2012